Few medtechs go public, but those that do, do nicely
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
Back to business for biotech flotations
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
Medtech IPOs rocketed just as stock markets faltered
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Moderna picks its moment
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Biotech flotations remain in high demand
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Floating device companies stay at home
Nine IPOs have got away so far this year, and one of them is very big indeed.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.